enVVeno Medical (NASDAQ:NVNO) Shares Up 0.8%

enVVeno Medical Corporation (NASDAQ:NVNO)’s share price shot up 0.8% during mid-day trading on Monday . The stock traded as high as $5.35 and last traded at $5.22. 22,184 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 115,594 shares. The stock had previously closed at $5.18.

enVVeno Medical Stock Performance

The stock has a market cap of $69.51 million, a P/E ratio of -2.72 and a beta of 1.17. The company’s fifty day moving average price is $5.55 and its 200-day moving average price is $4.83.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.32) earnings per share (EPS) for the quarter. Analysts anticipate that enVVeno Medical Corporation will post -1.4 earnings per share for the current fiscal year.

Insider Buying and Selling

In other enVVeno Medical news, CTO Hamed Alavi sold 8,334 shares of the company’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $6.22, for a total value of $51,837.48. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 17.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On enVVeno Medical

Large investors have recently added to or reduced their stakes in the stock. Fermata Advisors LLC bought a new stake in shares of enVVeno Medical during the third quarter valued at approximately $64,000. Armistice Capital LLC purchased a new position in enVVeno Medical during the 4th quarter worth $2,241,000. Finally, Kingdon Capital Management L.L.C. raised its position in enVVeno Medical by 182.5% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 619,180 shares of the company’s stock valued at $3,183,000 after purchasing an additional 400,000 shares in the last quarter. 34.71% of the stock is owned by hedge funds and other institutional investors.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).